Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment

[1]  T. Chenevert,et al.  Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma , 2011, PloS one.

[2]  D. Amelio,et al.  Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  K. Hunter,et al.  Making a Case , 2010 .

[4]  J. Sarkaria,et al.  Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks , 2010, Clinical Cancer Research.

[5]  R. Neubig,et al.  Reversible, Allosteric Small-Molecule Inhibitors of Regulator of G Protein Signaling Proteins , 2010, Molecular Pharmacology.

[6]  J. Hurst,et al.  Regulator of G-protein signaling (RGS) proteins in cancer biology. , 2009, Biochemical pharmacology.

[7]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Wei,et al.  Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. , 2009, Cancer research.

[9]  M. Cotton,et al.  G protein-coupled receptors stimulation and the control of cell migration. , 2009, Cellular signalling.

[10]  K. Murthy,et al.  Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathway. , 2009, American journal of physiology. Cell physiology.

[11]  M. Weller,et al.  Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. , 2009, Brain : a journal of neurology.

[12]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[13]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[14]  M. Weller,et al.  Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R , 2009, Stem cells.

[15]  D. Yee.  Faculty Opinions recommendation of Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009 .

[16]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[17]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[18]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[19]  M. Weller,et al.  Enzastaurin‐induced apoptosis in glioma cells is caspase‐dependent and inhibited by BCL‐XL , 2008, Journal of neurochemistry.

[20]  C. James,et al.  PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel , 2008, Clinical Cancer Research.

[21]  Zhihui Xie,et al.  R4 RGS proteins: regulation of G-protein signaling and beyond. , 2007, Pharmacology & therapeutics.

[22]  R. Motzer,et al.  Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[24]  P. Levitt,et al.  Making the Case for a Candidate Vulnerability Gene in Schizophrenia: Convergent Evidence for Regulator of G-Protein Signaling 4 (RGS4) , 2006, Biological Psychiatry.

[25]  M. Weller,et al.  Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12 , 2006 .

[26]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[27]  P. Wen,et al.  Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas , 2006, Neurology.

[28]  M. Weller,et al.  BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells , 2006, Cell Death and Differentiation.

[29]  Charles J. Wilson,et al.  RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion , 2006, Nature Neuroscience.

[30]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[31]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[32]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[34]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[35]  C. Tamminga,et al.  Regional expression of RGS4 mRNA in human brain † , 2004, The European journal of neuroscience.

[36]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Werner Paulus,et al.  Regulators of G‐Protein Signaling 3 and 4 (RGS3, RGS4) Are Associated with Glioma Cell Motility , 2004, Journal of neuropathology and experimental neurology.

[38]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[39]  In-Hyun Park,et al.  Regulation of Ribosomal S6 Kinase 2 by Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.

[40]  H. Dohlman.  Regulators of G Protein Signaling (RGS Proteins) , 2002 .

[41]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Sausville,et al.  Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  A Rimner,et al.  Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. , 2001, Cancer research.

[45]  B. Geoerger,et al.  Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.

[46]  Clive N Svendsen,et al.  A new method for the rapid and long term growth of human neural precursor cells , 1998, Journal of Neuroscience Methods.

[47]  D. Bigner,et al.  Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. , 1997, Neurosurgery.

[48]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[49]  R. McLendon,et al.  Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma , 2009, Journal of Neuro-Oncology.

[50]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[51]  K. Martemyanov,et al.  A role of RGS proteins in drug addiction. , 2008, Biochemical pharmacology.

[52]  M. Weller,et al.  Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. , 2006, Brain : a journal of neurology.

[53]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[54]  M. Farquhar,et al.  The regulator of G protein signaling family. , 2000, Annual review of pharmacology and toxicology.